Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
NeOnc Technologies announced an in-person End-of-Phase 1 Type B meeting with the FDA on Nov. 17, 2026 to discuss NEO212 development.Key Highlights:Original SEC Filing: NEONC TECHNOLOGIES HOLDINGS, INC. [ NTHI ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Conside…
The Nov. 17, 2026 in-person Type B meeting will cover Phase 2 study design, dose selection, endpoints and evidence for a future marketing application.
The meeting is set for Nov. 17, 2026. The company said Phase 1 results showed durable disease control in two heavily pretreated brain cancer patients.